Last update Nov. 21, 2022
It is a muscle relaxant with direct action on skeletal muscle. Oral administration for the symptomatic relief of severe chronic spasticity. Intravenous administration for the treatment of malignant hyperthermia.
It is excreted in breast milk in a very small concentration (Fricker 1998), much lower than the dose used in newborns and infants, and which would result in lower plasma levels than others that have been measured by placental transfer without side effects in newborns. (Fricker 1998, Shime 1988)
Dantrolene has been used in the neonatal period. (Tsutsumi 2021, Aguilar 1986)
The most common side effects are drowsiness, weakness, dizziness, malaise, fatigue, and diarrhea.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM